Suggested Readings

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Ader F, Bouscambert-Duchamp M, Hites M, et al. Lancet Infect Dis. 2022;22(2):209-221. 

Long COVID risk and pre-COVID vaccination: an EHR-based cohort study from the RECOVER program.

Brannock MD, Chew RF, Preiss AJ, et al. Preprint. Posted online October 7, 2022. medRxiv. 2022:2022.10.06.22280795.  

Persistent presence of spike protein and viral RNA in the circulation of individuals with post-acute sequelae of COVID-19.

Craddock V, Mahajan A, Krishnamachary B, et al. Preprint. Posted online August 9, 2022. medRxiv. 2022:2022.2008.2007.22278520. 

Dexamethasone in hospitalized patients with Covid-19.

Horby P, Lim WS, Emberson JR, et al. N Engl J Med. 2021;384(8):693-704.  

Immunopathogenesis and treatment of cytokine storm in COVID-19.

Kim JS, Lee JY, Yang JW, et al. Theranostics. 2021;11(1):316-329.  

A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia.

Makhoul E, Aklinski JL, Miller J, et al. Cureus. 2022;14(7):e27438.  

Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study.

Marrone A, Nevola R, Sellitto A, et al. Clin Infect Dis. 2022;75(1):e403-e409. 

Infliximab for treatment of adults hospitalized with moderate or severe Covid-19.

O’Halloran JA, Kedar E, Anstrom KJ, et al. Preprint. Posted online September 26, 2022. medRxiv. 2022:2022.2009.2022.22280245. 

Hospitalization and mortality among Black patients and White patients with Covid-19.

Price-Haywood EG, Burton J, Fort D, et al. N Engl J Med. 2020;382(26):2534-2543.   

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645. 

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group. Lancet. 2022;400(10349):359-368. 

The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19.

Rogers AJ, Wentworth D, Phillips A, et al. Ann Intern Med. 2022;175(10):1401-1410. 

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial.

Tomazini BM, Maia IS, Cavalcanti AB, et al. JAMA. 2020;324(13):1307-1316.  

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.

Wang Q, Iketani S, Li Z, et al. Cell. 2023;186(2):279-286.  

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.

WHO Solidarity Trial Consortium. Lancet. 2022;399(10339):1941-1953.  

Nirmatrelvir and the risk of post-acute sequelae of COVID-19.

Xie Y, Choi T, Al-Aly Z. Preprint. Posted online November 5, 2022. medRxiv. 2022:2022.2011.2003.22281783.   

Linked Resources
Related activities
0.75 CME/CE

Strengthening Your COVID-19 Management Technique

Exercising Best Practices for Patients Hospitalized With COVID-19

Faculty: Eric S. Daar, MD; Jens Lundgren, MD, DMSc
Release: 02/17/2023
Expiration: 02/17/2024